The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 16, 2018

Filed:

Feb. 18, 2015
Applicant:

Voom, Llc, Santa Barbara, CA (US);

Inventor:

Mark Silverberg, Santa Barbara, CA (US);

Assignee:

VOOM, LLC, Santa Barbara, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4174 (2006.01); A61K 31/4164 (2006.01); A61K 31/00 (2006.01); A61K 31/137 (2006.01); A61K 9/00 (2006.01); A61K 31/135 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4164 (2013.01); A61K 9/0048 (2013.01); A61K 31/00 (2013.01); A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61K 31/4174 (2013.01); Y10S 514/912 (2013.01);
Abstract

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.


Find Patent Forward Citations

Loading…